XCancer

[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers

Description:

This phase II study is assessing the correlation between M1/M2 macrophage polarization determined by tumor immunohistochemistry analysis and \[18F\]DPA-714 PET/CT binding (qualitative and texture analysis) in patients with operable triple negative breast cancer.

Sponsor:

Institut Cancerologie de l'Ouest

Phase:

Phase 2

Contacts:

Caroline ROUSSEAU, MD, PhD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT04320030 - Click here to see study on

ClinicalTrials.gov

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

DPA-714

Isotope(s):
Target(s):
  • TSPO
Ligand Class: Small Molecules
Inclusion
  • And HER2 (Human Epidermal Growth Factor Receptor-2) not amplified or not overexpressed
  • * 18 Years and older
  • And Progesterone receptors \< 10%
  • Triple negative primary breast cancer based on immunohistochemical results as follows:
  • Estrogen receptor \< 10%
Exclusion
  • * Patient with No triple negative breast cancer
  • Treated diabetes with fasting blood glucose \> 10 mmol/L
  • Patient with metastatic breast cancer
  • Patient with inflammatory breast cancer
  • Patient receiving cancer treatments such as chemotherapy, immunotherapy, biologic response modifiers, hormonal therapy, and radiotherapy BEFORE the biopsy and PET scans are performed